The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy

Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy

OncoImmunology ◽

10.1080/2162402x.2016.1221555 ◽

2016 ◽

Vol 5 (10) ◽

pp. e1221555 ◽

Cited By ~ 29

Author(s):

Diane Goltz ◽

Heidrun Gevensleben ◽

Jörn Dietrich ◽

Jörg Ellinger ◽

Jennifer Landsberg ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Promoter Methylation ◽

Immune Checkpoint ◽

Biochemical Recurrence ◽

Prognostic Biomarker ◽

MP72-15 DETERMINING THE MARGINAL BENEFIT OF ADJUVANT HORMONAL THERAPY IN INTERMEDIATE RISK PROSTATE CANCER PATIENTS WITH INSUFFICIENT DOSE DELIVERED BY PERMANENT PROSTATE BRACHYTHERAPY

The Journal of Urology ◽

10.1097/01.ju.0000557147.67693.22 ◽

2019 ◽

Vol 201 (Supplement 4) ◽

Author(s):

Jared Winoker* ◽

Rollin Say ◽

Conner Brown ◽

Richard Stock ◽

Nelson Stone

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Hormonal Therapy ◽

Prostate Brachytherapy ◽

Intermediate Risk ◽

Marginal Benefit ◽

Risk Prostate Cancer

Impact of Adjuvant Hormonal Therapy Duration and Timing of Salvage Hormonal Therapy in Prostate Cancer Patients With Unfavorable Prognosis Treated by Radiotherapy. A Secondary Analysis of RTOG 8531

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2007.07.308 ◽

2007 ◽

Vol 69 (3) ◽

pp. S170

Author(s):

L. Souhami ◽

K. Bae ◽

M.V. Pilepich ◽

H. Sandler

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Hormonal Therapy ◽

Secondary Analysis ◽

Adjuvant Hormonal Therapy

Does Adjuvant Hormonal Therapy Improve Freedom From Biochemical Relapse in Prostate Cancer Patients Receiving Dose-Escalated Radiation Therapy? An Analysis of RTOG 94-06

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2007.07.310 ◽

2007 ◽

Vol 69 (3) ◽

pp. S171 ◽

Cited By ~ 3

Author(s):

R.K. Valicenti ◽

K. Bae ◽

J. Michalski ◽

J. Cox ◽

W. Shipley ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Cancer Patients ◽

Hormonal Therapy ◽

Biochemical Relapse

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients

Epigenetics ◽

10.1080/15592294.2016.1241931 ◽

2016 ◽

Vol 11 (12) ◽

pp. 871-880 ◽

Cited By ~ 23

Author(s):

Sebastian Meller ◽

Lisa Zipfel ◽

Heidrun Gevensleben ◽

Jörn Dietrich ◽

Jörg Ellinger ◽

...

Keyword(s):

Prostate Cancer ◽

Gene Silencing ◽

Cancer Patients ◽

Promoter Methylation ◽

Biochemical Recurrence ◽

Prognostic Biomarker ◽

PD-L1promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy

Oncotarget ◽

10.18632/oncotarget.13161 ◽

2016 ◽

Vol 7 (48) ◽

pp. 79943-79955 ◽

Cited By ~ 35

Author(s):

Heidrun Gevensleben ◽

Emily Eva Holmes ◽

Diane Goltz ◽

Jörn Dietrich ◽

Verena Sailer ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Biochemical Recurrence ◽

Prognostic Biomarker ◽

Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients

The Prostate ◽

10.1002/pros.23244 ◽

2016 ◽

Vol 77 (3) ◽

pp. 255-262 ◽

Cited By ~ 2

Author(s):

Akihiro Asai ◽

Yasuyoshi Miyata ◽

Tomohiro Matsuo ◽

Yohei Shida ◽

Tomoaki Hakariya ◽

...

Keyword(s):

Prostate Cancer ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Cancer Patients ◽

Hormonal Therapy ◽

Vascular Endothelial ◽

Factor Expression ◽

Growth Factor Expression ◽

Endothelial Growth Factor

PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy

Clinical Epigenetics ◽

10.1186/s13148-016-0270-x ◽

2016 ◽

Vol 8 (1) ◽

Cited By ~ 5

Author(s):

Emily Eva Holmes ◽

Diane Goltz ◽

Verena Sailer ◽

Maria Jung ◽

Sebastian Meller ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Promoter Methylation ◽

Biochemical Recurrence ◽

Prognostic Biomarker ◽

Early Salvage Hormonal Therapy for Biochemical Failure Improved Survival in Prostate Cancer Patients After Neoadjuvant Hormonal Therapy Plus Radiation Therapy—A Secondary Analysis of Irish Clinical Oncology Research Group 97-01

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2012.03.001 ◽

2013 ◽

Vol 85 (1) ◽

pp. 101-108 ◽

Cited By ~ 15

Author(s):

Aminudin R. Mydin ◽

Mary T. Dunne ◽

Marie A. Finn ◽

John G. Armstrong

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Cancer Patients ◽

Clinical Oncology ◽

Hormonal Therapy ◽

Research Group ◽

Secondary Analysis ◽

Biochemical Failure ◽

Neoadjuvant Hormonal Therapy ◽

Oncology Research

Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

Breast Cancer Research ◽

10.1186/bcr2320 ◽

2009 ◽

Vol 11 (3) ◽

Cited By ~ 19

Author(s):

Christos Markopoulos ◽

Urania Dafni ◽

John Misitzis ◽

Vasilios Zobolas ◽

Evagelos Tzoracoleftherakis ◽

...

Keyword(s):

Breast Cancer ◽

Lipid Profile ◽

Cancer Patients ◽

Hormonal Therapy ◽

Detrimental Effect ◽

Postmenopausal Breast Cancer ◽

Breast Cancer Patients